What's Happening?
The African Development Bank (AfDB) has invested $15 million in Biovac, a biopharmaceutical company, to establish a new multi-vaccine production facility in Cape Town, South Africa. This facility aims to enhance Africa's capacity to produce vaccines locally,
including the continent's first inactivated polio vaccine and oral cholera vaccine. The initiative is part of a broader effort by Gavi, the Vaccine Alliance, and the World Health Organization (WHO) to support Africa's transition from a vaccine consumer to a producer. The facility is expected to be completed by 2028 and will significantly increase Biovac's manufacturing capacity to 500 million doses annually.
Why It's Important?
This development is crucial for Africa's health sovereignty, reducing dependency on imported vaccines, and strengthening regional value chains. By producing vaccines locally, Africa can better respond to health emergencies and reduce the burden of vaccine-preventable diseases. The project aligns with the African Union's goal to produce 60% of the continent's vaccines locally by 2040. It also supports the global health community's efforts to ensure equitable vaccine distribution and access, particularly in regions with high disease burdens.
What's Next?
Biovac's expansion will involve technology-transfer partnerships with international pharmaceutical companies, enhancing local expertise in vaccine production. The project will also integrate into Africa's emerging vaccine-financing architecture, including Gavi's African Vaccine Manufacturing Accelerator. This initiative will provide milestone payments and per-dose top-ups to African manufacturers, incentivizing local production. The success of this project could serve as a model for other regions seeking to enhance their vaccine production capabilities.
